[go: up one dir, main page]

MX2022002946A - Inhibidores de cdk y su uso como productos farmaceuticos. - Google Patents

Inhibidores de cdk y su uso como productos farmaceuticos.

Info

Publication number
MX2022002946A
MX2022002946A MX2022002946A MX2022002946A MX2022002946A MX 2022002946 A MX2022002946 A MX 2022002946A MX 2022002946 A MX2022002946 A MX 2022002946A MX 2022002946 A MX2022002946 A MX 2022002946A MX 2022002946 A MX2022002946 A MX 2022002946A
Authority
MX
Mexico
Prior art keywords
cdk inhibitors
pharmaceutical products
cdk
inhibitors
directed
Prior art date
Application number
MX2022002946A
Other languages
English (en)
Inventor
Rupa Shetty
Andrew Paul Combs
Liang Lu
Chaofeng Dai
Raul Andrew Leal
Klare Lazor Bersch
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of MX2022002946A publication Critical patent/MX2022002946A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La descripción se refiere, en parte, a los inhibidores de la CDK, a las composiciones farmacéuticas que comprenden los mismos, así como a los métodos de su uso y preparación.
MX2022002946A 2019-09-11 2020-09-11 Inhibidores de cdk y su uso como productos farmaceuticos. MX2022002946A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962898839P 2019-09-11 2019-09-11
US202063005577P 2020-04-06 2020-04-06
PCT/US2020/050326 WO2021050824A1 (en) 2019-09-11 2020-09-11 Cdk inhibitors and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
MX2022002946A true MX2022002946A (es) 2022-06-14

Family

ID=74850746

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002946A MX2022002946A (es) 2019-09-11 2020-09-11 Inhibidores de cdk y su uso como productos farmaceuticos.

Country Status (11)

Country Link
US (3) US20220324830A1 (es)
EP (1) EP4028005A4 (es)
JP (1) JP7763489B2 (es)
KR (1) KR20220079851A (es)
CN (1) CN114786673A (es)
AU (1) AU2020345950A1 (es)
BR (1) BR112022004327A2 (es)
CA (1) CA3153531A1 (es)
IL (1) IL291191A (es)
MX (1) MX2022002946A (es)
WO (1) WO2021050824A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220324830A1 (en) * 2019-09-11 2022-10-13 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
JP2023505850A (ja) * 2019-12-09 2023-02-13 石薬集団中奇制薬技術（石家庄）有限公司 サイクリン依存性キナーゼ９阻害剤としての化合物及びその用途
CN114605390B (zh) * 2020-12-04 2024-08-16 上海凌达生物医药有限公司 具有cdk激酶抑制活性的化合物、其药物组合物和用途
WO2022247785A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
WO2022247796A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
WO2023056441A1 (en) * 2021-09-30 2023-04-06 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
JP2024539631A (ja) * 2021-10-14 2024-10-29 プレリュード・セラピューティクス・インコーポレイテッド Ｃｄｋ９阻害剤として作用する置換ベンズイミダゾールの結晶形態およびその使用
WO2025076115A1 (en) * 2023-10-02 2025-04-10 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
US20250281473A1 (en) 2024-03-08 2025-09-11 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
CN119638640A (zh) * 2024-12-10 2025-03-18 杭州亦宁医药技术有限公司 一种5-溴-2-甲基-3-异丙基-吲唑的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010508301A (ja) * 2006-10-31 2010-03-18 スミスクライン ビーチャム コーポレーション ５−置換及び６−置換ベンゾイミダゾールチオフェン化合物
CN102046169B (zh) 2008-03-27 2013-03-13 雀巢产品技术援助有限公司 增加肽、肽模拟物和其他胃肠道转运蛋白底物吸收的方法
CA2767089A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
EP2964221B1 (en) * 2013-03-04 2017-12-06 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
BR112015021549A2 (pt) 2013-03-13 2017-07-18 Abbvie Inc inibidores de piridina cinase cdk9
EP3094326A4 (en) * 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CR20160363A (es) 2014-01-14 2016-10-12 Millennium Pharm Inc Heteroarilos y usos de estos
WO2016022312A1 (en) 2014-08-05 2016-02-11 Bristol-Myers Squibb Company Heterocyclic kinase inhibitors
US10787444B2 (en) 2015-06-05 2020-09-29 Syros Pharmaceuticals, Inc. Compounds for the modulation of myc activity
LT3539961T (lt) * 2015-06-29 2021-12-27 Astrazeneca Ab Policikliniai amido dariniai, kaip cdk9 inhibitoriai
WO2017051262A1 (en) 2015-09-22 2017-03-30 Hindustan Petroleum Corporation Limited An additive and a catalyst composition comprising the additive for fcc process
FR3041639B1 (fr) 2015-09-30 2019-01-25 Les Laboratoires Servier NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
CN107641118B (zh) 2016-07-22 2020-11-06 爱科诺生物医药股份有限公司 具有细胞坏死抑制活性的化合物及其组合物和应用
US20220324830A1 (en) * 2019-09-11 2022-10-13 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
JP2023505850A (ja) * 2019-12-09 2023-02-13 石薬集団中奇制薬技術（石家庄）有限公司 サイクリン依存性キナーゼ９阻害剤としての化合物及びその用途
WO2022035799A1 (en) * 2020-08-10 2022-02-17 Prelude Therapeutics Incorporated Heterocycle cdk inhibitors and their use thereof
AU2021345423A1 (en) * 2020-09-21 2023-05-11 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
MX2023007265A (es) * 2020-12-18 2023-08-14 Prelude Therapeutics Inc Inhibidores de cdk y su uso como productos farmacéuticos.
WO2023056441A1 (en) * 2021-09-30 2023-04-06 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
JP2024539631A (ja) * 2021-10-14 2024-10-29 プレリュード・セラピューティクス・インコーポレイテッド Ｃｄｋ９阻害剤として作用する置換ベンズイミダゾールの結晶形態およびその使用
WO2025076115A1 (en) * 2023-10-02 2025-04-10 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals

Also Published As

Publication number Publication date
EP4028005A1 (en) 2022-07-20
CA3153531A1 (en) 2021-03-18
WO2021050824A1 (en) 2021-03-18
US12486277B2 (en) 2025-12-02
AU2020345950A1 (en) 2022-03-31
IL291191A (en) 2022-05-01
US20220324830A1 (en) 2022-10-13
US11673893B2 (en) 2023-06-13
BR112022004327A2 (pt) 2022-05-31
US20210070761A1 (en) 2021-03-11
US20230242543A1 (en) 2023-08-03
KR20220079851A (ko) 2022-06-14
JP7763489B2 (ja) 2025-11-04
CN114786673A (zh) 2022-07-22
EP4028005A4 (en) 2023-09-20
JP2022548568A (ja) 2022-11-21

Similar Documents

Publication Publication Date Title
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
MX2019011764A (es) Composiciones limpiadoras y usos de las mismas.
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
MX2019008696A (es) Compuestos de piridina como inhibidores de shp2 alostericos.
EP4230627A3 (en) Inhibitors of the menin-mll interaction
MY197720A (en) Bicyclic heterocycles as fgfr inhibitors
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
MX372914B (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
SG10201907582WA (en) Bicyclic heterocycles as fgfr4 inhibitors
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
UA115677C2 (uk) ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
BR112017001796A2 (pt) composições de flagelina e seus usos
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
MX382832B (es) Benzimidazoles sustituidos, su preparación y su uso como productos farmacéuticos.
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич